Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Ardelyx Inc (ARDX)

Ardelyx Inc (ARDX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Ardelyx Inc 400 Fifth Avenue Suite 210 Waltham MA 02451 USA

www.ardelyx.com Employees: 267 P: 510-745-1700

Description:

Ardelyx, Inc. is a clinical-stage biopharmaceutical company. It discovers, develops and commercializes small molecule therapeutics that work in the gastrointestinal tract to treat cardio-renal, GI and metabolic diseases. The Company's lead product candidate is Tenapanor which is in three ongoing Phase II clinical trials for the treatment of patients with ESRD-HD and chronic kidney disease, as well as for constipation-predominant irritable bowel syndrome. Ardelyx, Inc. is headquartered in Fremont, California.

Key Statistics

Overview:

Market Capitalization, $K 1,257,695
Enterprise Value, $K 1,286,045
Shares Outstanding, K 236,854
Annual Sales, $ 124,460 K
Annual Net Income, $ -66,070 K
Last Quarter Sales, $ 98,240 K
Last Quarter Net Income, $ -810 K
EBIT, $ -64,070 K
EBITDA, $ -62,780 K
60-Month Beta 0.92
% of Insider Shareholders 5.90%
% of Institutional Shareholders 58.92%
Float, K 222,880
% Float 94.10%
Short Volume Ratio 0.27

Growth:

1-Year Return 23.20%
3-Year Return 494.96%
5-Year Return -28.53%
5-Year Revenue Growth 4,668.58%
5-Year Earnings Growth 81.48%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 0.00 on 10/31/24
Next Earnings Date N/A
Earnings Per Share ttm -0.30
EPS Growth vs. Prev Qtr 100.00%
EPS Growth vs. Prev Year -100.00%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

ARDX Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -46.60%
Return-on-Assets % -21.49%
Profit Margin % -53.09%
Debt/Equity 0.64
Price/Sales 9.74
Price/Cash Flow N/A
Price/Book 7.66
Book Value/Share 0.67
Interest Coverage -6.39
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar